시장보고서
상품코드
1301427

안과용 의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Ophthalmic Drugs Market (Therapeutic Class: Anti-VEGF Agents, Anti-glaucoma Drugs, Anti-inflammatory Drugs, Anti-infective Drugs, Anti-allergy Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 292 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

안약 시장 - 보고서의 범위

TMR의 세계 안과용 의약품 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 세계 안과용 의약품 시장의 수익을 제공합니다. 2017년부터 2031년까지 기간 중 2023년을 기준 연도, 2031년을 예측 연도로 간주합니다. 이 보고서는 또한 2023-2031년간 세계 안과용 의약품 시장의 복합 연간 성장률(CAGR%)을 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 분석가들이 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하여 주요 조사 활동의 대부분을 수행했으며, 2차 조사에서는 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조를 통해 안과용 의약품 시장을 파악했습니다.

이 보고서는 세계의 안과용 의약품 시장 경쟁 구도를 자세히 분석합니다. 세계 안과용 의약품 시장에서 활동하는 주요 기업이 식별되며, 이들은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 안과용 의약품 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 서론
  • 개요
  • 시장 역학
  • 세계 시장 볼륨 예측 : 제형별, 2017-2031

제5장 주요 인사이트

  • 세계 주요 국가의 질병 유병률과 이환율
  • 파이프라인 분석
  • 주요 업계 이벤트
  • COVID-19 팬데믹이 업계에 미치는 영향

제6장 세계 시장 분석과 예측 : 치료 클래스별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 치료제 클래스별, 2017-2031
    • 항VEGF제
    • 항녹내장제
      • Alpha Agonist
      • Beta Blockers
      • Prostaglandin Analogs
      • Combined Medication
      • 기타
    • 항염증제
      • 스테로이드
      • NSAID
    • 항감염증제
      • 항생제
      • 항진균제
      • 기타
    • 항알레르기약
    • 기타
  • 시장 매력 분석 : 치료제 클래스별

제7장 세계 시장 분석과 예측 : 적응증별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 적응증별, 2017-2031
    • 안구건조증
    • 녹내장
    • 감염증/염증
    • 망막 질환
      • 습성 AMD
      • 건성 AMD
      • 당뇨병성 망막증
      • 기타
    • 알레르기
    • 포도 막염
    • 기타
  • 시장 매력 분석 : 적응증별

제8장 세계 시장 분석과 예측 : 투여 경로별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 투여 경로별, 2017-2031
    • 경구
    • 국소 안구(유리체 내)
    • 기타
  • 시장 매력 분석 : 투여 경로별

제9장 세계 시장 분석과 예측 : 제품 유형별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 제품 유형별, 2017-2031
    • 처방
    • OTC
  • 시장 매력 분석 : 제품 유형별

제10장 세계 시장 분석과 예측 : 제형별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 제형별, 2017-2031
    • 아이드롭
    • 점안액 및 현탁액
    • 캡슐 및 정제
    • 연고
    • 기타
  • 시장 매력 분석 : 제형별

제11장 세계 시장 분석과 예측 : 유통 채널별

  • 서론과 정의
  • 주요 조사 결과와 개발
  • 시장 매출 예측 : 유통 채널별, 2017-2031
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 분석 : 유통 채널별

제12장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 : 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제13장 북미 시장 분석과 예측

제14장 유럽 시장 분석과 예측

제15장 아시아태평양 시장 분석과 예측

제16장 라틴아메리카 시장 분석과 예측

제17장 중동 및 아프리카 시장 분석과 예측

제18장 경쟁 구도

  • 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
  • 시장 점유율 분석 : 기업별, 2022년
  • 기업 개요
    • AbbVie, Inc.
    • Alcon Vision LLC
    • Bausch Health Companies, Inc.
    • Bayer AG
    • Coherus BioSciences
    • F. Hoffmann-La Roche Ltd.
    • Novartis Pharmaceuticals Corporation
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
LSH 23.07.14

Ophthalmic Drugs Market - Scope of Report

TMR's report on the global Ophthalmic Drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Ophthalmic Drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Ophthalmic Drugs market.

The report delves into the competitive landscape of the global Ophthalmic Drugs market. Key players operating in the global Ophthalmic Drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs market profiled in this report.

Key Questions Answered in Global Ophthalmic Drugs Market Report:

  • What is the sales/revenue generated by Ophthalmic Drugs across all regions during the forecast period?
  • What are the opportunities in the global Ophthalmic Drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Ophthalmic Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global Ophthalmic Drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ophthalmic Drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031

5. Key Insights

  • 5.1. Disease Prevalence & Incidence rate globally with key countries
  • 5.2. Pipeline Analysis
  • 5.3. Key Industry Events
  • 5.4. Covid-19 Pandemic Impact on the Industry

6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 6.3.1. Anti-VEGF Agents
    • 6.3.2. Anti-glaucoma Drugs
      • 6.3.2.1. Alpha Agonist
      • 6.3.2.2. Beta Blockers
      • 6.3.2.3. Prostaglandin Analogs
      • 6.3.2.4. Combined Medication
      • 6.3.2.5. Others
    • 6.3.3. Anti-inflammatory Drugs
      • 6.3.3.1. Steroids
      • 6.3.3.2. NSAIDs
    • 6.3.4. Anti-infective Drugs
      • 6.3.4.1. Anti-bacterial Drugs
      • 6.3.4.2. Anti-fungal Drugs
      • 6.3.4.3. Others
    • 6.3.5. Anti-allergy Drugs
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Therapeutic Class

7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. Dry Eye
    • 7.3.2. Glaucoma
    • 7.3.3. Infection/Inflammation
    • 7.3.4. Retinal Disorders
      • 7.3.4.1. Wet AMD
      • 7.3.4.2. Dry AMD
      • 7.3.4.3. Diabetic Retinopathy
      • 7.3.4.4. Others
    • 7.3.5. Allergy
    • 7.3.6. Uveitis
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Topical
    • 8.3.2. Local Ocular (intravitreal)
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Product Type, 2017-2031
    • 9.3.1. Prescription
    • 9.3.2. OTC
  • 9.4. Market Attractiveness Analysis, by Product Type

10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 10.3.1. Eye Drops
    • 10.3.2. Eye Solutions & Suspensions
    • 10.3.3. Capsules & Tablets
    • 10.3.4. Gels
    • 10.3.5. Ointments
    • 10.3.6. Others
  • 10.4. Market Attractiveness Analysis, by Dosage Form

11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Attractiveness Analysis, by Distribution Channel

12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness Analysis, by Region

13. North America Ophthalmic Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 13.2.1. Anti-VEGF Agents
    • 13.2.2. Anti-glaucoma Drugs
      • 13.2.2.1. Alpha Agonist
      • 13.2.2.2. Beta Blockers
      • 13.2.2.3. Prostaglandin Analogs
      • 13.2.2.4. Combined Medication
      • 13.2.2.5. Others
    • 13.2.3. Anti-inflammatory Drugs
      • 13.2.3.1. Steroids
      • 13.2.3.2. NSAIDs
    • 13.2.4. Anti-infective Drugs
      • 13.2.4.1. Anti-bacterial Drugs
      • 13.2.4.2. Anti-fungal Drugs
      • 13.2.4.3. Others
    • 13.2.5. Anti-allergy Drugs
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Dry Eye
    • 13.3.2. Glaucoma
    • 13.3.3. Infection/Inflammation
    • 13.3.4. Retinal Disorders
      • 13.3.4.1. Wet AMD
      • 13.3.4.2. Dry AMD
      • 13.3.4.3. Diabetic Retinopathy
      • 13.3.4.4. Others
    • 13.3.5. Allergy
    • 13.3.6. Uveitis
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Topical
    • 13.4.2. Local Ocular (intravitreal)
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Product Type, 2017-2031
    • 13.5.1. Prescription
    • 13.5.2. OTC
  • 13.6. Market Value Forecast, by Dosage Form, 2017-2031
    • 13.6.1. Eye Drops
    • 13.6.2. Eye Solutions & Suspensions
    • 13.6.3. Capsules & Tablets
    • 13.6.4. Gels
    • 13.6.5. Ointments
    • 13.6.6. Others
  • 13.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.7.1. Hospital Pharmacies
    • 13.7.2. Retail Pharmacies
    • 13.7.3. Online Pharmacies
  • 13.8. Market Value Forecast, by Country, 2017-2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Therapeutic Class
    • 13.9.2. By Indication
    • 13.9.3. By Route of Administration
    • 13.9.4. By Product Type
    • 13.9.5. By Dosage Form
    • 13.9.6. By Distribution Channel
    • 13.9.7. By Country

14. Europe Ophthalmic Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 14.2.1. Anti-VEGF Agents
    • 14.2.2. Anti-glaucoma Drugs
      • 14.2.2.1. Alpha Agonist
      • 14.2.2.2. Beta Blockers
      • 14.2.2.3. Prostaglandin Analogs
      • 14.2.2.4. Combined Medication
      • 14.2.2.5. Others
    • 14.2.3. Anti-inflammatory Drugs
      • 14.2.3.1. Steroids
      • 14.2.3.2. NSAIDs
    • 14.2.4. Anti-infective Drugs
      • 14.2.4.1. Anti-bacterial Drugs
      • 14.2.4.2. Anti-fungal Drugs
      • 14.2.4.3. Others
    • 14.2.5. Anti-allergy Drugs
    • 14.2.6. Others
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Dry Eye
    • 14.3.2. Glaucoma
    • 14.3.3. Infection/Inflammation
    • 14.3.4. Retinal Disorders
      • 14.3.4.1. Wet AMD
      • 14.3.4.2. Dry AMD
      • 14.3.4.3. Diabetic Retinopathy
      • 14.3.4.4. Others
    • 14.3.5. Allergy
    • 14.3.6. Uveitis
    • 14.3.7. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Topical
    • 14.4.2. Local Ocular (intravitreal)
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Product Type, 2017-2031
    • 14.5.1. Prescription
    • 14.5.2. OTC
  • 14.6. Market Value Forecast, by Dosage Form, 2017-2031
    • 14.6.1. Eye Drops
    • 14.6.2. Eye Solutions & Suspensions
    • 14.6.3. Capsules & Tablets
    • 14.6.4. Gels
    • 14.6.5. Ointments
    • 14.6.6. Others
  • 14.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.7.1. Hospital Pharmacies
    • 14.7.2. Retail Pharmacies
    • 14.7.3. Online Pharmacies
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Spain
    • 14.8.5. Italy
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Therapeutic Class
    • 14.9.2. By Indication
    • 14.9.3. By Route of Administration
    • 14.9.4. By Product Type
    • 14.9.5. By Dosage Form
    • 14.9.6. By Distribution Channel
    • 14.9.7. By Country/Sub-region

15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 15.2.1. Anti-VEGF Agents
    • 15.2.2. Anti-glaucoma Drugs
      • 15.2.2.1. Alpha Agonist
      • 15.2.2.2. Beta Blockers
      • 15.2.2.3. Prostaglandin Analogs
      • 15.2.2.4. Combined Medication
      • 15.2.2.5. Others
    • 15.2.3. Anti-inflammatory Drugs
      • 15.2.3.1. Steroids
      • 15.2.3.2. NSAIDs
    • 15.2.4. Anti-infective Drugs
      • 15.2.4.1. Anti-bacterial Drugs
      • 15.2.4.2. Anti-fungal Drugs
      • 15.2.4.3. Others
    • 15.2.5. Anti-allergy Drugs
    • 15.2.6. Others
  • 15.3. Market Value Forecast, by Indication, 2017-2031
    • 15.3.1. Dry Eye
    • 15.3.2. Glaucoma
    • 15.3.3. Infection/Inflammation
    • 15.3.4. Retinal Disorders
      • 15.3.4.1. Wet AMD
      • 15.3.4.2. Dry AMD
      • 15.3.4.3. Diabetic Retinopathy
      • 15.3.4.4. Others
    • 15.3.5. Allergy
    • 15.3.6. Uveitis
    • 15.3.7. Others
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.4.1. Topical
    • 15.4.2. Local Ocular (intravitreal)
    • 15.4.3. Others
  • 15.5. Market Value Forecast, by Product Type, 2017-2031
    • 15.5.1. Prescription
    • 15.5.2. OTC
  • 15.6. Market Value Forecast, by Dosage Form, 2017-2031
    • 15.6.1. Eye Drops
    • 15.6.2. Eye Solutions & Suspensions
    • 15.6.3. Capsules & Tablets
    • 15.6.4. Gels
    • 15.6.5. Ointments
    • 15.6.6. Others
  • 15.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.7.1. Hospital Pharmacies
    • 15.7.2. Retail Pharmacies
    • 15.7.3. Online Pharmacies
  • 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Therapeutic Class
    • 15.9.2. By Indication
    • 15.9.3. By Route of Administration
    • 15.9.4. By Product Type
    • 15.9.5. By Dosage Form
    • 15.9.6. By Distribution Channel
    • 15.9.7. By Country/Sub-region

16. Latin America Ophthalmic Drugs Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 16.2.1. Anti-VEGF Agents
    • 16.2.2. Anti-glaucoma Drugs
      • 16.2.2.1. Alpha Agonist
      • 16.2.2.2. Beta Blockers
      • 16.2.2.3. Prostaglandin Analogs
      • 16.2.2.4. Combined Medication
      • 16.2.2.5. Others
    • 16.2.3. Anti-inflammatory Drugs
      • 16.2.3.1. Steroids
      • 16.2.3.2. NSAIDs
    • 16.2.4. Anti-infective Drugs
      • 16.2.4.1. Anti-bacterial Drugs
      • 16.2.4.2. Anti-fungal Drugs
      • 16.2.4.3. Others
    • 16.2.5. Anti-allergy Drugs
    • 16.2.6. Others
  • 16.3. Market Value Forecast, by Indication, 2017-2031
    • 16.3.1. Dry Eye
    • 16.3.2. Glaucoma
    • 16.3.3. Infection/Inflammation
    • 16.3.4. Retinal Disorders
      • 16.3.4.1. Wet AMD
      • 16.3.4.2. Dry AMD
      • 16.3.4.3. Diabetic Retinopathy
      • 16.3.4.4. Others
    • 16.3.5. Allergy
    • 16.3.6. Uveitis
    • 16.3.7. Others
  • 16.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 16.4.1. Topical
    • 16.4.2. Local Ocular (intravitreal)
    • 16.4.3. Others
  • 16.5. Market Value Forecast, by Product Type, 2017-2031
    • 16.5.1. Prescription
    • 16.5.2. OTC
  • 16.6. Market Value Forecast, by Dosage Form, 2017-2031
    • 16.6.1. Eye Drops
    • 16.6.2. Eye Solutions & Suspensions
    • 16.6.3. Capsules & Tablets
    • 16.6.4. Gels
    • 16.6.5. Ointments
    • 16.6.6. Others
  • 16.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 16.7.1. Hospital Pharmacies
    • 16.7.2. Retail Pharmacies
    • 16.7.3. Online Pharmacies
  • 16.8. Market Value Forecast, by Country/Sub-region,2017-2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Therapeutic Class
    • 16.9.2. By Indication
    • 16.9.3. By Route of Administration
    • 16.9.4. By Product Type
    • 16.9.5. By Dosage Form
    • 16.9.6. By Distribution Channel
    • 16.9.7. By Country/Sub-region

17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Therapeutic Class, 2017-2031
    • 17.2.1. Anti-VEGF Agents
    • 17.2.2. Anti-glaucoma Drugs
      • 17.2.2.1. Alpha Agonist
      • 17.2.2.2. Beta Blockers
      • 17.2.2.3. Prostaglandin Analogs
      • 17.2.2.4. Combined Medication
      • 17.2.2.5. Others
    • 17.2.3. Anti-inflammatory Drugs
      • 17.2.3.1. Steroids
      • 17.2.3.2. NSAIDs
    • 17.2.4. Anti-infective Drugs
      • 17.2.4.1. Anti-bacterial Drugs
      • 17.2.4.2. Anti-fungal Drugs
      • 17.2.4.3. Others
    • 17.2.5. Anti-allergy Drugs
    • 17.2.6. Others
  • 17.3. Market Value Forecast, by Indication, 2017-2031
    • 17.3.1. Dry Eye
    • 17.3.2. Glaucoma
    • 17.3.3. Infection/Inflammation
    • 17.3.4. Retinal Disorders
      • 17.3.4.1. Wet AMD
      • 17.3.4.2. Dry AMD
      • 17.3.4.3. Diabetic Retinopathy
      • 17.3.4.4. Others
    • 17.3.5. Allergy
    • 17.3.6. Uveitis
    • 17.3.7. Others
  • 17.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 17.4.1. Topical
    • 17.4.2. Local Ocular (intravitreal)
    • 17.4.3. Others
  • 17.5. Market Value Forecast, by Product Type, 2017-2031
    • 17.5.1. Prescription
    • 17.5.2. OTC
  • 17.6. Market Value Forecast, by Dosage Form, 2017-2031
    • 17.6.1. Eye Drops
    • 17.6.2. Eye Solutions & Suspensions
    • 17.6.3. Capsules & Tablets
    • 17.6.4. Gels
    • 17.6.5. Ointments
    • 17.6.6. Others
  • 17.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 17.7.1. Hospital Pharmacies
    • 17.7.2. Retail Pharmacies
    • 17.7.3. Online Pharmacies
  • 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Therapeutic Class
    • 17.9.2. By Indication
    • 17.9.3. By Route of Administration
    • 17.9.4. By Product Type
    • 17.9.5. By Dosage Form
    • 17.9.6. By Distribution Channel
    • 17.9.7. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (by tier and size of companies)
  • 18.2. Market Share Analysis, by Company, 2022
  • 18.3. Company Profiles
    • 18.3.1. AbbVie, Inc.
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Financial Overview
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Strategic Overview
    • 18.3.2. Alcon Vision LLC
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Financial Overview
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Strategic Overview
    • 18.3.3. Bausch Health Companies, Inc.
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Financial Overview
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Strategic Overview
    • 18.3.4. Bayer AG
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Financial Overview
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Strategic Overview
    • 18.3.5. Coherus BioSciences
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Financial Overview
      • 18.3.5.4. SWOT Analysis
      • 18.3.5.5. Strategic Overview
    • 18.3.6. F. Hoffmann-La Roche Ltd.
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Financial Overview
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Novartis Pharmaceuticals Corporation
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Financial Overview
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Pfizer, Inc.
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Financial Overview
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Strategic Overview
    • 18.3.9. Regeneron Pharmaceuticals, Inc.
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Financial Overview
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Santen, Inc.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Financial Overview
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Strategic Overview
    • 18.3.11. Sun Pharmaceutical Industries Ltd.
      • 18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. Financial Overview
      • 18.3.11.4. SWOT Analysis
      • 18.3.11.5. Strategic Overview
    • 18.3.12. Teva Pharmaceutical Industries Ltd.
      • 18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. Financial Overview
      • 18.3.12.4. SWOT Analysis
      • 18.3.12.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제